MX2017007381A - Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. - Google Patents
Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.Info
- Publication number
- MX2017007381A MX2017007381A MX2017007381A MX2017007381A MX2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A
- Authority
- MX
- Mexico
- Prior art keywords
- maf
- musculoadoneurotic
- oncogen
- homology
- human fibrosarcoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090599P | 2014-12-11 | 2014-12-11 | |
| PCT/IB2015/059562 WO2016092524A1 (en) | 2014-12-11 | 2015-12-11 | Binding members for human c-maf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007381A true MX2017007381A (es) | 2017-11-06 |
Family
ID=55024191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007381A MX2017007381A (es) | 2014-12-11 | 2015-12-11 | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10793642B2 (https=) |
| EP (1) | EP3229909B1 (https=) |
| JP (1) | JP2017538412A (https=) |
| KR (1) | KR20170093182A (https=) |
| CN (1) | CN107001480B (https=) |
| AU (1) | AU2015358868A1 (https=) |
| BR (1) | BR112017012515A2 (https=) |
| CA (1) | CA2967224C (https=) |
| MX (1) | MX2017007381A (https=) |
| WO (1) | WO2016092524A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108192972B (zh) | 2010-10-06 | 2022-09-09 | 生物医学研究机构基金会 | 用于乳腺癌转移的诊断、预后和治疗的方法 |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| ES2906586T3 (es) | 2012-10-12 | 2022-04-19 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata |
| US20160040247A1 (en) | 2013-03-15 | 2016-02-11 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis, and tratment of cancer metastasis |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| US11596642B2 (en) | 2016-05-25 | 2023-03-07 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| KR20200104298A (ko) | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9509957D0 (en) | 1995-05-17 | 1995-07-12 | Khalil Nasreen | Post-translational activation of tgf-1 involving the tsp-1 receptor cd36 |
| US5814468A (en) | 1996-03-27 | 1998-09-29 | Coulter International Corp. | Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution |
| US5958671A (en) | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
| US6242213B1 (en) | 1996-12-23 | 2001-06-05 | Immunex Corporation | Isolated DNA molecules encoding RANK-L |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| CN1362947A (zh) | 1999-03-15 | 2002-08-07 | Axys药物公司 | 用作蛋白酶抑制剂的n－氰基甲基酰胺 |
| WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
| DE60126592T2 (de) | 2000-04-03 | 2007-11-22 | Corixa Corp., Hamilton | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| PH12012502440A1 (en) | 2001-06-26 | 2013-06-17 | Amgen Inc | Antibodies to opgl |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| IL162111A0 (en) | 2001-12-22 | 2005-11-20 | 4Antibody Ag | Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| ES2886923T3 (es) | 2005-09-20 | 2021-12-21 | Menarini Silicon Biosystems Spa | Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US8785150B2 (en) | 2006-06-30 | 2014-07-22 | University Of Southern California | Quantifiable internal reference standards for immunohistochemistry and uses thereof |
| WO2008086800A2 (en) | 2007-01-15 | 2008-07-24 | Aarhus Universitet | Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| CN101772511A (zh) | 2007-02-16 | 2010-07-07 | 太平洋艾瑞有限公司 | 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用 |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| JPWO2010110346A1 (ja) | 2009-03-24 | 2012-10-04 | 独立行政法人理化学研究所 | 白血病幹細胞マーカー |
| WO2011039734A2 (en) | 2009-10-02 | 2011-04-07 | Enzo Medico | Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer |
| CN108192972B (zh) | 2010-10-06 | 2022-09-09 | 生物医学研究机构基金会 | 用于乳腺癌转移的诊断、预后和治疗的方法 |
| CA2826657A1 (en) | 2011-02-04 | 2012-08-09 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| ES2906586T3 (es) * | 2012-10-12 | 2022-04-19 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160040247A1 (en) | 2013-03-15 | 2016-02-11 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis, and tratment of cancer metastasis |
| DK3055429T3 (en) | 2013-10-09 | 2019-04-23 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| US11596642B2 (en) | 2016-05-25 | 2023-03-07 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| KR20200104298A (ko) | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
-
2015
- 2015-12-11 KR KR1020177018132A patent/KR20170093182A/ko not_active Withdrawn
- 2015-12-11 MX MX2017007381A patent/MX2017007381A/es unknown
- 2015-12-11 WO PCT/IB2015/059562 patent/WO2016092524A1/en not_active Ceased
- 2015-12-11 EP EP15816535.7A patent/EP3229909B1/en active Active
- 2015-12-11 US US15/534,893 patent/US10793642B2/en active Active
- 2015-12-11 CA CA2967224A patent/CA2967224C/en active Active
- 2015-12-11 CN CN201580067068.4A patent/CN107001480B/zh active Active
- 2015-12-11 BR BR112017012515-3A patent/BR112017012515A2/en not_active Application Discontinuation
- 2015-12-11 AU AU2015358868A patent/AU2015358868A1/en not_active Abandoned
- 2015-12-11 JP JP2017530686A patent/JP2017538412A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001480B (zh) | 2021-12-03 |
| JP2017538412A (ja) | 2017-12-28 |
| US20170369589A1 (en) | 2017-12-28 |
| CN107001480A (zh) | 2017-08-01 |
| AU2015358868A1 (en) | 2017-06-01 |
| BR112017012515A2 (en) | 2018-01-02 |
| CA2967224A1 (en) | 2016-06-16 |
| US10793642B2 (en) | 2020-10-06 |
| EP3229909A1 (en) | 2017-10-18 |
| KR20170093182A (ko) | 2017-08-14 |
| CA2967224C (en) | 2023-08-22 |
| WO2016092524A1 (en) | 2016-06-16 |
| EP3229909B1 (en) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| MX2017007381A (es) | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA202092435A3 (ru) | Моноклональные антитела против bcma | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| PL3129063T3 (pl) | Koniugat lek-przeciwciało anty-her3 | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| PL3101032T3 (pl) | Koniugat przeciwciało anty-HER2-lek | |
| HUE046027T2 (hu) | Multispecifikus ellenanyag-konstrukciók | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| MX2016016886A (es) | Anticuerpos anti-axl. | |
| EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| SI3200822T1 (sl) | Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171) | |
| IL249250B (en) | Novel combinations for antigen based therapy | |
| IL269559A (en) | Stable multispecific antibodies | |
| EP3251607C0 (en) | ACHILLES TENDON SUTURE INSTRUMENT | |
| CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| EP3589320A4 (en) | ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION | |
| EP3756626C0 (en) | ASTRAGALOCALCANEAN JOINT IMPLANT | |
| DK3154587T3 (da) | Konjugater omfattende et anti-egfr1-antistof |